SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Clinical trial NCT06239480 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06239480
- Sponsor
- Palvella Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-31
- Primary completion
- 2026-01-14
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.